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Chylothorax is a condition of lymph leakage and accumulation in the pleural space caused by damage to the thoracic duct. Chylothorax is a 
rare medical complication, with an incidence rate of apt
proximately 2% of all adult pleural effusion.1 It can be 
potentially dangerous and fatal, with an average of 10% 
mortality and morbidity.1
 The causes of this abnormality are either traumatic 
or nonttraumatic. The signs and symptoms are also dit
vided into two major groups: the ones related to fluid 
persistence in the pleural space (respiratory complicat
tion), and the ones related to body lymph wasting (het
modynamic, nutritional, metabolic and immunologic 
complications). 
 We evaluated a patient who was suffering from low 
grade lymphoma and a mild pleural effusion. While bet
ing treated these conditions, he developed chylothorax 
on his left side, which continued despite response of the 
underlying lymphoma to chemotherapy. The patient 
eventually recovered without any treatment. 
CASE
A 67tyeartold nontsmoking man was referred to our 
medical center in April 2008. He had been suffering 
from fever, sweat, and acute onset of cough without 
any indication of weight loss. A chest CT scan showed 
an anterior mediastinal mass. The patient had upper 
gastrointestinal hemorrhage. Upon undergoing upper 
endoscopy, a large and active duodenal ulcer was dist
covered. Further tests revealed a large splenomegaly 
with an aberrant spleen, left side pleural effusion, rett
rotperitoneal and parataortic lymphadenopathies, and 
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chylothorax is a rare complication with both traumatic and non-traumatic causes. the most common 
non-traumatic cause is malignancy, especially lymphoma. lymph discharges into the pleural space, 
causing nutritional, metabolic, immunologic and respiratory complications. We evaluated the case of 
a patient suffering from a low-grade lymphoma who developed chylothorax that did not respond to 
chemotherapy and conservative treatment. this patient recovered spontaneously.
a ninetmillimeter nodule in the liver suspected to be 
a hemangioma. A CTtguided biopsy on the mediastit
nal mass confirmed lowtgrade lymphoma (B cell type). 
Further evaluations confirmed bone marrow involvet
ment with lymphoma. 
Chemotherapy was began with fludarabine (25 mg/
m2 for three days), cyclophosphamide (300 mg/m2 for 
three days), rituximab (375 mg/m2 on day one), and 
dexamethasone (32 mg for three days). After three 
courses of chemotherapy, evaluation indicated a 75% 
response to the treatment, with the spleen and adt
enopathy dimensions becoming much smaller than bet
fore, and the mediastinal mass size was reduced from 
7 cm to 3 cm. However, the pleural effusion volume 
increased.
After the fourth course of chemotherapy, the patient 
developed dyspnea. Chest Xtray showed lefttsided 
pleural effusion, for which diagnostic thoracentesis was 
performed. The biochemistry analysis of the drained 
chylous fluid showed triglyceride levels of over 2000 
mg/dL, cholesterol levels of 106 mg/dL, and a white 
blood cell level of 4t6 per high power field on light mit
croscopy, which confirmed chylothorax. Culture and 
smear were negative for any pathogens and acid fast bat
cilli. Three days after the fifth course, 2.5 liters of chyt
lous fluid was drained from the patient’s pleural space 
to reduce respiratory symptoms. The same volume 
was drained a month later, following the sixth course. 
Twentyttwo days after the second drainage, three more 
liters of chylous fluid was again drained.
 The patient was followed up every other week for 
the next three months. During the early stages of follow 
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up, the fluid had a steady volume. This amount started 
to decline in the later stages. Chest xtray showed no 
fluid in the pleural space. The two subsequent examit
nations, one a month and the second three months aft
ter the xtray appeared normal, without the symptoms 
of underlying and complicated disease. This shows 
an appropriate response of lymphoma to treatment 
and spontaneous recovery of chylothorax. The patient 
gained weight and  was performing daily work after 
one year of followtup.
DISCuSSION
Thoracic duct damage and subsequent chylothorax 
can have traumatic and nonttraumatic causes (Table 
1). Iatrogenic causes form the majority of traumatic 
group where thoracic surgery, especially esophagectot
my is predominant.2 In the nonttraumatic group, mat
lignancies especially lymphoma, are the most common 
causes.2,.3
 Depending on its specific cause, the mechanism of 
thoracic duct damage and chylothorax onset is either 
direct trauma to the duct or compression of it by a mass 
or adenopathy or even infiltration of a tumor into the 
duct, causing rupture or perforation.4 In Kaposi sarcot
ma, obstruction of the thoracic duct leads to the lymph 
excretion from duct wall, hence the chylothorax.2
A cluster of clinical signs of chylothorax is the prest
ence of lymph fluid in the pleural space, which leads 
to respiratory symptoms. Severity of symptoms and 
signs depends on both the leakage quantity and durat
tion. When trauma is the cause of chylothorax, print
cipal clinical signs are usually similar to any kind of 
pleural effusion like dyspnea, cough, and chest discomt
fort. Pleuritic pain of chest wall and fever are unusual 
because lymph does not irritate the pleural surface.5 
The signs of the underlying disease are usually more 
dominant than respiratory signs in the nonttraumatic 
group.
 The other cluster of clinical signs and symptoms 
in chylothorax is related to body lymph loss, and int
cludes the following condition: hypovolemia (in acute 
or severe cases), nutritional signs (loss of gastrointestit
nal absorbed fat and necessary vitamins), immunologic 
signs (loss of lymphocytes), metabolic and electrot
lyte signs (loss of protein and electrolytes can lead to 
Hyponatremia, hypocalcemia, and acidosis).1
 Depending on the cause of thoracic duct damage, 
chylothorax occurs on the right or the left hemithorax 
or bilaterally (especially in traumatic causes). Nonttraut
matic chylothorax, especially after malignancies, occurs 
on the left side or bilaterally.4,6 According to one study, 
independent of cause, half the cases of all chylothorax 
were on the right side, onetthird on the left side, and the 
rest were bilateral.7
Chest radiographic findings in chylothorax are nont
specific and undistinguishable from other pleural effut
sions although chest or abdomen CT scan may prove 
useful in nonttraumatic chylothorax because of identit
fying lymph nodes or masses.1 A definite diagnosis is 
made by thoracentesis and evaluation of drained pleut
ral fluid. Mostly, the fluid appears milky (in patients 
who fast or on a low fat diet, the fluid color may not be 
milky). Serous, bloody, turbid fluids do not exclude chyt
lothorax. Loculated and infectious fluid is rare and this 
is possibly due to lymphocyte dominancy.8 Red blood 
cells are usually seen in traumatic chylothorax. A high 
level of triglyceride of pleural fluid (more than 110 mg/
dL) is diagnostic for chylothorax. A lower quantity is 
confirmed by lipoprotein electrophoresis, which shows 
chylomicrons in pleural fluid.
 The cholesterol concentration should be evaluated 
because of pseudochylothorax, which is important in 
Table 1. Classifications of more common causes for chylothorax.
   Group Subgroup Diseases
   Congenital    delivery trauma-lymphatic anomalies
  Traumatic    iatrogenic Thorax surgery-neck radical dissection, abdomen lymph node dissection, internal jugular or subclavian vein cannulation
   non-iatrogenic Penetrating trauma, blunt trauma
   non traumatic    Malignancy Lymphoma, metastatic carcinoma, Kaposi sarcoma
   infectious Tuberculosis, filariasis 
   Vein Thrombosis Subclavian vein thrombosis 
   Others Mediastinal radiotherapy, pancreatitis/pseudocyst of pancreas, hypothyroidism, nephrotic syndrome
  Pseudochylothorax Tuberculosis, rheumatoid arthritis 
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the differential diagnosis. Pseudochylothorax, also 
called cholesterol chylothorax, is a chronic accumulat
tion of cholesterol rich fluid (more than 200 mg/dL). 
The fluid color is turbid, green or yellow and may be 
mistaken with real chylothorax or empyema. This cont
dition is usually accompanied with diseases causing 
chronic pleural effusions like tuberculosis and rheut
matoid arthritis. There is a theory that the cholesterol 
comes from broken inflammatory cells which have ret
mained in the pleural space for a long time.5
The approach to treatment depends on the cause 
of the chylothorax. When fluid is found in the pleural 
space, the first step is to perform diagnostic thoracentet
sis. When the diagnosis is definite and respiratory signs 
are severe, the priority is fluid evacuation by setting a 
chest tube or occasionally drainage by thoracentesis. The 
next step, depending on severity of fluid accumulation, 
is to decrease lymph production by a lowtfat dietary 
regimen, which contains mediumtchain triglyceride 
(directly absorbed into the blood via the portal system) 
or to use total parental nutrition (TPN). Somatostatin 
or octreotide are also reported to have been effective in 
decreasing lymph production.9t11
 Further measures are taken depending on the cause 
of chylothorax. When the cause is traumatic or congent
ital,13 the rupture will be closed spontaneously in 50% 
of cases by conservative treatment (exceptions are the 
cases that occur after esophagectomy, which has a high 
mortality rate as well as severe cases where, despite sett
ting a drainage line, immunologic, metabolic and nutrit
tional signs are predominant and the patient needs int
tensive care for hypovolemia).1 In nonttraumatic cases, 
surgery is usually excluded and conservative or underlyt
ing disease treatment should be considered.1,5
 Radiotherapy or chemotherapy in cases with mat
lignancies may be useful, but, depending on the severt
ity of underlying disease, the treatment can be disapt
pointing.13,14 If malignancy does not respond to chemot
therapy or radiotherapy, pleurodesis is performed using 
bleomycin, talc or other substances.15 According to the 
results of one study on 19 patients suffering from ret
fractory chylothorax caused by lymphoma, pleurodesis 
under thoracoscopy was successful in 100 percent of 
the cases.16 Time of surgery in chylothorax is still cont
troversial. Surgery recommended as the first measure 
in severe traumatic cases or chylothorax after surgery, 
especially esophagectomy.
Surgery is also recommended when the leakage rate 
of lymph is more than one liter per day in a period of 
five days or when conservative treatment for 2 weeks 
fails or there is loculation or fibrin clots with chylothot
rax.5,17t19 Using lymphangiography or eating fat marked 
by methylene blue or injection of Evans blue dye into 
the intratarsal space can be useful for localizing the thot
racic duct leakage along surgery.5
 Unlike other pleural effusions, chylothorax is a rare 
complication that needs special attention. The evaluat
tion of pleural fluid triglyceride as a complementary 
procedure may seem useful in most diagnostic thorat
centesis. Determining the chylothorax etiology is an 
important underlying step in choosing management 
and treatment. The influence of chylothorax on lymt
phoma prognosis is uncertain. Although the occurrence 
of chylothorax suggests poor prognosis,20t22 this was not 
the case for our patient. Spontaneous recovery of chyt
lothorax, especially a in nonttraumatic case, is rare, and 
treatment of underlying disease is usually a necessity. 
Sometimes the treatment of underlying disease worst
ens the chylothorax. This often occurs in malignancies 
where tumor invades the thoracic duct such that a rupt
ture or orifice remains on the duct after the regression 
of tumor by treatment. In our patient, despite chemot
therapy and proper response of underlying disease to 
treatment, chylothorax remained. However, the rupture 
recovered and chylothorax disappeared without any 
food restriction or hospitalization.
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